Automating Data Analysis for the Characterization of Biotherapeutics Candidates
Daniela Tomazela, PhD, Associate Principal Scientist, Biology-Discovery, Mass Spectrometry, Merck, Kenilworth, NJ, USA
Presented at the 10th Annual Biotherapeutics Analytical Summit 2019 in Alexandria, VA, USA.
As part of discovery-developability, sequence-variant evaluation and analysis of stressed samples are critical steps on the path toward final candidate selection. The diverse and large volumes of data generated during the evaluation of molecules’ intactness, sequence coverage, and potential liabilities makes producing reports cumbersome and time-consuming. In this talk, Dr. Tomazela focused on MS analysis of biotherapeutic candidates to demonstrate an implementation of data analysis automation in support of early-discovery.